Table 4.
Model 1: key drivers of direct costs in patients with tuberous sclerosis complex with epilepsy during the most recent 3-year period
| Variable | p Value |
| Single manifestation categories | |
| Brain | 0.9533 |
| Circulatory | 0.5882 |
| Dermatological | 0.2704 |
| Kidney and urinary | 0.1282 |
| Psychiatric | 0.7628 |
| Respiratory | 0.5999 |
| Combinations of manifestation categories | |
| Brain/circulatory | 0.1846 |
| Brain/dermatological | 0.5965 |
| Brain/kidney and urinary | 0.5621 |
| Brain/psychiatric | 0.2749 |
| Dermatological/circulatory | 0.5965 |
| Dermatological/kidney and urinary | 0.0012 |
| Dermatology/psychiatric | 0.1023 |
| Kidney and urinary/circulatory | 0.1341 |
| Kidney and urinary/psychiatric | 0.6255 |
p Values are generated from a gamma distribution regression assessing the significance of manifestations in driving tuberous sclerosis complex-associated costs.